Montreal startup Thorasys has landed a $1.3 million investment from members of the Anges Québec investor group.
Thorasys offers pulmonary function test equipment for the diagnosis and monitoring of lung diseases like asthma and COPD.
In a release the company said the cash will allow it to better commercialize the tremoFlo™ C-100 Airwave Oscillometry System, a portable device that diagnoses lung diseases in order to improve treatment, with minimal patient effort.
“We didn’t invent the measurement technique… we made it cheaper, more portable, more attractive and with software that’s easier to use,” VP Sébastien Jutras told La Presse’s Marc Tison.
Thorasys was founded in 2014 by two McGill University respiratory science researchers, Geoffrey Maksym and CEO Thomas Schuessler. Over $4 million and four years of research went into the product before Anges Quebec stepped in.
Thorasys’ tremoFlo product is available in about 24 countries where 100 units have been sold for about $15,000 each. The company’s US approval should come in a few weeks, noted Tison.
Current techniques require “substantial effort and coordination” by patients and healthcare professionals. Thorasys, meanwhile, developed a technology for assessing lung function “without patient effort.”
The technology provides a detailed assessment of changes in and around the lungs, making it possible to detect lung diseases faster. These are the two major advantages that set Thorasys apart from the competition.
“The expertise developed by Thorasys over the years… were key factors in our decision to support Thomas and his team,” said Marcel Larochelle and Xavier Harland, two angel investors. “We’re happy our contribution will help Thorasys pursue its successful growth.”